Cetuximab concomitant with gemcitabine and radiotherapy in advanced squamous cell carcinomas of upper aerodigestive tract: a pilot study

García, Martín Granados; Rosas, María Fátima Chilaca; Lozano, Arturo Javier Lavín; Magos, Federico Maldonado; Mendivil, Mauricio Frías; Aquino, Gustavo Cabrera; Pacheco, Blanca Angélica Segura; Luis, María Montserrat Montes; Caraza, D. O.; Ponce, José Luis Aguilar

doi:10.1007/s12094-011-0627-8

Cited by 5 publications

(2 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Granados García et al [25] explored CTX, gemcitabine, and RT in 20 patients. Weekly CTX was administered at conventional doses, gemcitabine at 50 mg/m 2 for 7 weekly cycles, and classic RT until 70 Gy.…”

Section: Resultsmentioning

confidence: 99%

Advanced Squamous Cell Carcinoma of the Head and Neck: The Current Role of Cetuximab

Granados-García

Aguilar-Ponce²,

Maldonado-Magos³

et al. 2016

ORL

View full text Add to dashboard Cite

We review clinical trials of squamous cell carcinoma of the head and neck (SCCHN) to address the current and potential uses of cetuximab (CTX). PubMed was reviewed to identify papers published between 2010 and 2016. The search terms used were “cetuximab” and “head and neck cancer.” A total of 634 articles were identified. Phase II or III studies with CTX in patients with advanced SCCHN without treatment or with recurrent/metastatic tumors were selected. Forty-six registries were obtained. Information was critically reviewed and relevant information presented. As definitive treatment of advanced squamous cells carcinomas and as palliative treatment of recurrent/metastatic disease, CTX alone or associated with chemotherapy and/or radiotherapy is an alternative to chemoradiotherapy because of its distinct and favorable toxicity profile.

show abstract

Section: Resultsmentioning

confidence: 99%

Advanced Squamous Cell Carcinoma of the Head and Neck: The Current Role of Cetuximab

Granados-García

Aguilar-Ponce²,

Maldonado-Magos³

et al. 2016

ORL

View full text Add to dashboard Cite

show abstract

“…A recent pilot study that investigated the administration of cetuximab concomitantly with gemcitabine and radiotherapy in advanced squamous cell carcinoma of the upper aerodigestive tract, reported that the toxicity was significant (24). However, the combination of gemcitabine with cetuximab was sufficiently effective in HNSCC in vitro and regimens of cetuximab administered concomitantly with gemcitabine and radiotherapy are highly likely to cause side effects.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of gemcitabine and cetuximab combination treatment in head and neck squamous cell carcinoma

Maseki

Ijichi

Nakanishi

et al. 2013

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Head and neck squamous cell carcinoma (HNSCC) may be curable with surgery, radiation and chemotherapy in its early stages. However, recurrence and metastasis often prevail following primary treatment in advanced stage cases and are associated with significant morbidity and mortality. In this study we investigated the combination therapy of gemcitabine and cetuximab for HNSCC. The UM-SCC-6 and UM-SCC-23 HNSCC cell lines were analyzed following treatment with gemcitabine and cetuximab. To determine the mechanism of action of this combination treatment, the cell cycle distributions following gemcitabine and/or cetuximab treatment were analyzed by flow cytometry and apoptosis assay. Gemcitabine and cetuximab combination treatment exerted an enhanced cytotoxic effect. The cell cycle analysis demonstrated that cells accumulated in the S phase following gemcitabine treatment and G1 arrest occurred following cetuximab treatment. An increase in sub-G1 phase cells was also observed following treatment with the two drugs. In an apoptosis assay, caspase 3/7 activity was found to be higher when administering a combination of gemcitabine and cetuximab compared to each agent administered alone. Gemcitabine and cetuximab are individually effective against HNSCC and an enhanced growth inhibitory effect may be expected when these agents are used in combination.

show abstract

Advanced cutaneous squamous cell carcinoma: how is it defined and what new therapeutic approaches are available?

Soura

Gagari

Stratigos

2019

Current Opinion in Oncology

View full text Add to dashboard Cite

Purpose of review Despite the overall excellent survival rates in patients with cutaneous squamous cell carcinoma (cSCC), advanced cutaneous SCCs are associated with high patient morbidity and mortality. Therefore, important unmet clinical needs persist: identifying high risk patients and choosing optimal treatment approaches. Recent findings In recent years, a better understanding of the biology of cSCC and its clinical progression have led to improved staging systems and new promising treatments for advanced disease. Such treatments include PD1 inhibitors, such as cemiplimab, which was recently approved for the treatment of cutaneous SCC, and pembrolizumab whose efficacy in the treatment cSCC is still being investigated. Other treatments, such as epidermal growth factor receptor inhibitors have also been used in the treatment of cSCC with moderate success. Several clinical and histological risk factors are considered key in estimating the risk or recurrence or metastasis in cSCCs and, therefore, influence the appropriate treatment choice and patient monitoring. Summary The present study reviews the current definition of advanced cSCC and discusses the new systemic approaches, including checkpoint inhibitors.

show abstract

Cetuximab concomitant with gemcitabine and radiotherapy in advanced squamous cell carcinomas of upper aerodigestive tract: a pilot study

Abstract: Although toxicity is important, this approach has interesting activity and deserves further investigation.

Cited by 5 publications

References 20 publications

Advanced Squamous Cell Carcinoma of the Head and Neck: The Current Role of Cetuximab

Advanced Squamous Cell Carcinoma of the Head and Neck: The Current Role of Cetuximab

Efficacy of gemcitabine and cetuximab combination treatment in head and neck squamous cell carcinoma

Advanced cutaneous squamous cell carcinoma: how is it defined and what new therapeutic approaches are available?

Contact Info

Product

Resources

About